- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05999175
Open-label Trial Evaluating Four Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste, and Mouthwash
Evaluation of the Tolerability, Safety of Use, and Efficacy of Cosmetic Products for the Oral Care. In Use Test Under Dentist Control
Study Overview
Status
Conditions
Intervention / Treatment
- Device: the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
- Device: the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial " Spazzolino tau-marin®" 3 times a day after the main meals for 28 days.
- Device: subjects of this group will use their routine oral hygiene products.
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pavia
-
San Genesio ed Uniti, Pavia, Italy, 27010
- Studio D. Cattaneo
-
San Martino Siccomario, Pavia, Italy, 27028
- Complife Italia Srl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy Caucasian males and females aged ≥ 18 to ≤ 65 years included.
- Proper oral hygiene not performed verified with Simplified Oral Hygiene Index (OHI-S) (score ≥ 2) and a questionnaire on oral habit.
- Patients able to comply with the requirements for the study and freely willing to provide written informed consent to the collection of their data.
- Registered with Italian National Health Service (NHS).
- Ability to understand the language used in the investigation center and to comply with the study procedures.
- Unbanned pharmacological therapy stable for at least one month without any changes during the study.
- Commitment not to change the daily routine and lifestyle.
Exclusion Criteria:
- Allergies or sensitivity to oral care products, cosmetic products, drugs, patch or medical devices.
- Any oral cavity condition inappropriate for participation.
- Gums bleeding due to pathologies/pharmacological treatment.
- Concomitant or during the last week antibiotic therapy.
- Smokers (≥5 cigarettes/day).
- Acute, chronic or progressive diseases/illness/conditions able to interfere with the outcome of the study or considered dangerous or incompatible with the study requirements.
- Pathological staining of teeth.
- Breast-feeding, pregnancy, or women of child-bearing age unwilling to take the necessary precautions to avoid pregnancy during the study.
- Planning to participate or participation in other clinical trials withing 30 days.
- Hospitalization/planned hospitalization in a health or social facility.
- Deprivation of freedom by administrative or legal decision or under guardianship
- Inability to be contacted in case of emergency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Group 1 (20 subjects)
using the delicate mint toothpaste "Dentifricio gel tau-marin® Menta Delicata".
|
the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
|
|
Other: Group 2 (12 subjects)
using of the mint toothpaste "Dentifricio gel tau-marin® Menta".
|
the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
|
|
Other: Group 3 (20 subjects)
using the mint mouthwash "Collutorio tau-marin® Menta.
|
the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
|
|
Other: Group 4 (20 subjects)
using the delicate mint toothpaste "Dentifricio gel tau-marin® Menta Delicata", mint mouthwash "Collutorio tau-marin® Menta".
|
the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial " Spazzolino tau-marin®" 3 times a day after the main meals for 28 days.
|
|
Other: Group 5 (12 subjects)
continuing to use their routine oral hygiene products.
|
subjects of this group will use their routine oral hygiene products.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gums sensitivity
Time Frame: 28 days
|
Change from baseline to day 14 and 28 days assessed by the Investigator during the dentist examination using a 10 cm visual analogue scale (VAS) where 0 is absence of sensitivity and 10 indicates the maximum of sensitivity.
|
28 days
|
|
Rate of gingival irritations
Time Frame: 28 days
|
Change from baseline to 14 and 28 days assessed by the Investigator during the dentist examination as follows: (Yes presence of gingival irritation; No = absence of gingival irritation).
|
28 days
|
|
Rate of oral mucosa lesions
Time Frame: 28 days
|
Change from baseline to 14 and 28 days assessed by the Investigator during the dentist examination as follows: (Yes presence of oral mucosa lesion; No = absence of oral mucosa lesion).
|
28 days
|
|
Dental plaque assessment
Time Frame: 1 day
|
Change from T0 (at the baseline at visit, performed three hours after the last teeth brushing) to Timm (evaluation done immediately after the first product use).
The evaluation is carried out by means of an erythrosine-based disclosing tablet, which allows to quantify the presence of plaque on the teeth.
First, the dentist gives the tablet to the subjects, who are asked to chew it thoroughly in their mouths.
Then, the subjects are asked to rub the chewed particles of the tablets on their teeth with their tongue and swish the accumulated saliva in their mouth for about 60 seconds before rinsing with water.
The releasing tablet stains the plaque on the teeth.
|
1 day
|
|
Teeth colour assessment
Time Frame: 28 days
|
Change from baseline to 14 and 28 days as assessed by the investigator during the dentist's examination comparing the subjects' teeth with those shown on the VITAPAN® Score.
The scoring system consists of a series of 16 "artificial teeth" in 16 different colors, each of which is associated with an alphanumeric code representing the entire chromatic space of natural teeth.
It classifies tooth color into 4 families of shades as follows: reddish-brownish (A1, A2, A3, A3.5, A4), reddish-yellowish (B1, B2, B3, B4), grayish (C1, C2, C3, C4) and reddish-grey (D2, D3, D4).
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-assessment questionnaire
Time Frame: 28 days
|
Subjects are asked to complete a self-report questionnaire on Timm (immediately after first use) and on days 14 and 28.
|
28 days
|
|
Oral microbiota analysis
Time Frame: 28 days
|
It evaluates the change from baseline to 28 days. Oral microbiota is obtained by brushing a defined area of the mouth. Swabs are collected and stored at room temperature. Microbiome analysis is based on metagenomic analysis of the 16S rRNA gene. The second step in the analysis pipeline is to isolate the bacterial DNA from other components of the sample. Through a series of cell lysis and extraction steps, the purified bacterial material is obtained. The bacterial material is then amplified by PCR, first to increase the amount of DNA, and second to label the genetic material - which will later allow identification of each sample during the sequencing step. The concentrations of the samples are equalized prior to pooling to create the sequencing mix. This solution is then loaded into a cartridge and analyzed by a sequencer. The biodiversity index (Shannon index) and statistics are calculated using a dedicated software (Microbiome analyst) |
28 days
|
|
Serious Adverse Events/Adverse Events
Time Frame: 14 days
|
The number of participants with treatment-related adverse events will be assessed by CTCAE v6.0
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dario Cattaneo, DDS, San Genesio ed Uniti, Pavia (Italy)
Publications and helpful links
General Publications
- Willis JR, Gabaldon T. The Human Oral Microbiome in Health and Disease: From Sequences to Ecosystems. Microorganisms. 2020 Feb 23;8(2):308. doi: 10.3390/microorganisms8020308.
- Abdulkareem AA, Al-Taweel FB, Al-Sharqi AJB, Gul SS, Sha A, Chapple ILC. Current concepts in the pathogenesis of periodontitis: from symbiosis to dysbiosis. J Oral Microbiol. 2023 Apr 2;15(1):2197779. doi: 10.1080/20002297.2023.2197779. eCollection 2023.
- Kilian M, Chapple IL, Hannig M, Marsh PD, Meuric V, Pedersen AM, Tonetti MS, Wade WG, Zaura E. The oral microbiome - an update for oral healthcare professionals. Br Dent J. 2016 Nov 18;221(10):657-666. doi: 10.1038/sj.bdj.2016.865.
- Rajendiran M, Trivedi HM, Chen D, Gajendrareddy P, Chen L. Recent Development of Active Ingredients in Mouthwashes and Toothpastes for Periodontal Diseases. Molecules. 2021 Apr 1;26(7):2001. doi: 10.3390/molecules26072001.
- Rosu S, Benatti P, Bianco S, Barattini DF, Nobile V, Mellai M, Cattaneo D. Pilot, open-label, randomized controlled clinical trial evaluating 4 oral hygiene regimens using a manual toothbrush, toothpaste, and mouthwash. Gen Dent. 2024 Jul-Aug;72(4):62-71.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0002847/21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.